Held by 3 specialist biotech funds
High Convergence# Signal Note: Avoro Capital Initiates $134M Position in Soleno Therapeutics Avoro Capital's substantial entry into SLNO signals confidence in dihydropeucedanol (SLEN-001) for Prader-Willi syndrome, a rare genetic disorder with limited treatment options and unmet metabolic needs.
AI analyst context — unlock full analysis
# Signal Note: Rock Springs Capital Initiates $11.4M Position in Soleno Therapeutics Rock Springs' new $11.4M position in SLNO suggests conviction in the company's lead program, dibotermin alfa (SOL-004), in development for congenital lipodystrophy—a rare metabolic disorder with limited treatment options and orphan drug designation. The timing likely reflects upcoming clinical catalysts; SLNO is advancing toward Phase 3 readout expected in late 2024/early 2025, with potential for accelerated regulatory pathway given unmet need. For a healthcare specialist fund trading concentrated positions, the entry signals confidence in near-term binary event resolution and commercial viability in the rare disease space.
+ 1more — see how much conviction went in
See the Full Story